Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at least moderate idiopathic or diabetic gastroparesis
Latest Information Update: 30 May 2025
At a glance
- Drugs Naronapride (Primary)
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Therapeutic Use
- Acronyms MOVE-IT
- Sponsors Dr Falk Pharma
Most Recent Events
- 27 May 2025 Status changed from recruiting to active, no longer recruiting, According to Renexxion media release.
- 27 May 2025 According to Renexxion media release, company announced the successful completion of patient enrollment, and with topline results expected in the second half of 2025.
- 04 Feb 2025 Planned End Date changed from 1 Apr 2025 to 1 Dec 2025.